David P. Dearnaley, MD, of The Royal Marsden NHS Foundation Trust, discusses the comparison, in this study, of hypofractionated high-dose IMRT schedules for prostate cancer (Abstract 2).
Bernard J. Escudier, MD, of the Institut Gustave Roussy, discusses a subgroup analyses of this phase III study of cabozantinib vs everolimus in patients with advanced renal cell carcinoma (Abstract 499). To see the French language version of this video, click here.
Paul L. Nguyen, MD, of Dana-Farber Cancer Institute, discusses this phase III trial in which prostate cancer patients were given antiandrogen therapy with bicalutamide during and after salvage radiation therapy following radical prostatectomy and an elevated PSA (Abstract 3).
Bernard J. Escudier, MD, of the Institut Gustave Roussy, discusses in French a subgroup analyses of this phase III study of cabozantinib vs everolimus in patients with advanced renal cell carcinoma (Abstract 499).
Toni Choueiri, MD, of the Dana-Farber Cancer Institute, summarizes key points from a session he chaired on clear and non-clear cell renal cancer, including information on molecular genetics and its impact on treatment, how to treat patients with non-clear cell histology, and the best strategy for treating clear cell cancer.
Bishoy M. Faltas, MD, of Weill Cornell Medical College, discusses his team’s work using whole exome sequencing, which may have important implications for selecting patients for immunotherapeutic approaches (Abstract 354).
